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1. Introduction 
Sepsis is the most important cause of morbidity and mortality in the intensive care unit 
(ICU), but it lacks specific clinical manifestations. As a result, sensitive and specific 
indicators of infection that can be collected easily and that accurately reflect infection 
severity and prognosis are highly coveted and are clinically important. Currently, common 
clinical indicators of infection include pyrexia, white blood cell (WBC) counts, C-reactive 
protein (CRP), and procalcitonin (PCT). However, in clinical settings, the limitation of CRP 
and PCT for assessing the severity and predicting prognosis may affect the clinician’s ability 
to effectively evaluate the change in septic patients’ general condition that would indicate 
deterioration and even impending death. Therefore, looking for new biomarkers with high 
sensitivity and specificity is one of the main research fields in sepsis. The objective of this 
paper is to review new biomarkers that are ….  
2. TREM-1 
Triggering receptor expressed on myeloid cells-1 (TREM-1) is a recently discovered member 
of the immunoglobulin superfamily of receptors that is expressed on polymorphonuclear 
granulocytes and mature monocytes. Bacterial or fungal infections may induce its 
expression.  
2.1. Soluble TREM-1 
sTREM-1 is a soluble form of TREM-1 that may be released into body fluids upon the 
upregulated expression of TREM-1(Bouchon A,et al. 2001). An increasing number of studies 
indicate that there are increased levels of sTREM-1 in body fluid samples for the following 
diseases and conditions: sepsis, pneumonia, pleural effusion, septic arthritis, meningitis, 
peritonitis, and uterine cavity infection (Gibot S, et al. 2004) (Gibot S, et al. 2004) (Liu CL, et 
al. 2007) (Collins CE,et al. 2009) (Determann RM, et al. 2006) (Kusanovic JP, et al.2010) 
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(Determann RM, et al. 2009). This suggests that sTREM-1 may be a valuable diagnostic 
indicator for making distinctions between infectious and non-infectious diseases. It has also 
been found that septic shock patients have high levels of serum sTREM-1 that are closely 
related to the severity of infection, and sTREM-1 has a good positive correlation with the 
Sequential Organ Failure Assessment (SOFA) score (Gibot S, et al. 2004) (Dimopoulou I, et 
al. 2009). With regard to sepsis prognosis, dynamic changes in serum sTREM-1 may provide 
warnings concerning the life or death of patients (Zhang J, et al. 2011) (Gibot S, et al. 2005).  
Urine sTREM-1 is more sensitive than WBC counts, serum CRP, and serum PCT for the 
early diagnosis of sepsis, as well as for dynamic assessments of severity and prognosis. It 
can also provide an early warning of possible secondary acute kidney injury (AKI) in sepsis 
patients (Su LX, et al. 2011).  
In terms of diagnostic value for ventilator-associated pneumonia (VAP), the combination of 
sTREM-1 plus Clinical Pulmonary Infection Score (CPIS) improved the ability to diagnose 
VAP. Moreover, logistic regression analysis showed that sTREM-1 is an independent risk 
factor for VAP (Su LX, et al. for publication). We also found that sTREM-1 is of no use in 
determining bacteremia-caused, new fever in ICU patients, but sTREM-1 levels correlate 
with the prognosis of patients with bacteremia (Su LX, et al. for publication). 
2.2. Genetics and TREM-1 
More and more studies have confirmed that sepsis is caused by factors both environmental 
and genetic and that from the pathological point of view, genetic factors outweigh 
environmental factors. Therefore, clarification of how genetic factors are associated with 
sepsis may increase the awareness of susceptibility and prognosis concerning the disease. A 
study investigating an association between TREM-1 gene polymorphisms and severe sepsis 
concluded that 3 studied common polymorphisms within the TREM-1 gene (rs7768162, 
rs9471535, and rs2234237) may not play a major role in the predisposition to severe sepsis in 
a Chinese Han cohort (Chen Q, et al. 2008). However, Jung et al (Jung ES,et al. 2011) proved 
that TREM-1 SNPs (rs7768162, rs9471535, and rs2234237) may play a significant role in the 
development of intestinal Behcet's disease and may have modest effects on disease severity. 
Recently, in our study, we found that 2 variations (rs2234246 and rs2234237) within the 
TREM-1 gene are not correlated with susceptibility to sepsis. However, the TREM-1 
rs2234237 polymorphism is associated with high 28-day mortality among sepsis patients, 
constituting a risk factor affecting prognosis (Su LX, et al. for publication). Therefore, TREM-
1 could be a fairly ideal genetic biomarker for the diagnosis and prognosis of sepsis. 
3. CD163 
CD163 is a transmembrane molecule, hitherto only discovered on the membrane of 
mononuclear phagocytes. As a specific scavenger receptor for hemoglobin/heme inside the 
body, it is capable of specific recognition of the hemoglobin-haptoglobin complex. Studies in 
recent years have found that CD163 regulates the expression of anti-inflammatory 
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molecules, such as Interleukin-10 (IL-10) and Hemeoxigenase-1 (HO-1) (Moestrup SK, et 
al.2004) (Graversen JH, et al.2002).  
3.1. Soluble CD163 
Soluble CD163 (sCD163) comes from CD163 molecules that peel off the membrane of 
mononuclear cells (Moestrup SK, et al.2004) (Hogger P, et al. 2001). Blood levels of sCD163 
have prognostic value for several inflammatory diseases and may have use in clinical 
applications as a biomarker of inflammatory diseases. Our prospective, clinical study 
confirmed that the serum sCD163 level might have potential value for the diagnosis of 
sepsis and severe sepsis, and its performance was superior to PCT and CRP levels. sCD163 
also would have advantages for the dynamic monitoring of sepsis development and 
prognosis and have favorable prospects for use in clinical applications (Feng L, et al. for 
publication). 
3.2. Soluble CD163 and sepsis prognosis 
We compared sTREM-1, sCD163 and other clinical parameters for their assessment value for 
sepsis (Su LX, et al, for publication). On the day of ICU admission, the sepsis group 
displayed higher levels of serum sTREM-1, sCD163, PCT, and CRP than the Systemic 
Inflammatory Response Syndrome (SIRS) group (P<.05). Although PCT, sTREM-1 and 
SOFA score were good markers to identify the severity of sepsis, sTREM-1 was the most 
reliable of these 3 markers. That is because serum sTREM-1 was a risk factor related to 
sepsis (OR=1.089, 95% confidence interval [CI] 1.045–1.136, P<.001). Its area under the 
Receiver Operating Characteristics (ROC) curve, meant for diagnosis, was 0.978 (95% CI, 
0.958–0.997), and that for severity evaluation was 0.9 (95% CI, 0.823–0.977). Sensitivity and 
specificity were 0.91 and 0.87 respectively. On observation days 1, 3, 5, 7, 10, and 14, serum 
sCD163, sTREM-1, PCT and SOFA score continued to climb among non-survivors, while 
WBC and CRP levels decreased. In contrast, various indicators from the survivors showed a 
tendency to decline. The curves show that the non-survivors registered higher serum 
sTREM-1, sCD163, WBC and PCT levels, as well as SOFA score over an observation period 
of 14 days. Both sCD163 and SOFA score were independent factors impacting the survival 
time (sCD163 hazard ratio =1.09, 95% CI, 1.035–1.154, P<.001; SOFA score hazard ratio=1.23, 
95% CI, 1.126–1.335, P<.001). Their areas under the ROC curve, denoting prognosis, 
measured 0.696 (95% CI, 0.593-0.799) and 0.794 (95% CI, 0.705–0.833), respectively. With 2.84 
mg/L as the cutoff point for sCD163, sensitivity measured 0.535 and specificity was 0.789. In 
summary, the serum sCD163 level could be the most useful diagnostic value indicator for 
dynamic assessment of sepsis prognosis (Su LX, et al, for publication) . 
3.3. Soluble CD163 and kidney disease 
Some studies in patients with bacteremia report high serum sCD163 expression, which has 
prognostic value (Gaini S, et al. 2008) (Moller HJ, et al. 2006), and high serum sCD163 
expression also occurs in people with chronic kidney diseases (Axelsson J, et al. 2006). The 
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CD163-hemoglobin scavenger receptor plays an important role in the process of the 
clearance and conversion of hemoglobin/heme in chronic kidney disease (Simoni J, et al. 
2006). At present, it is unknown whether sCD163 can be detected in urine and what value it 
may possess for sepsis and secondary AKI. Recently, our team evaluated for the first time 
the potential value of urine sCD163 for sepsis and secondary AKI diagnosis, as well as for 
early assessment of prognosis. Our results demonstrated in an indirect manner the causes 
behind urine phagocyte increase and revealed a possible mechanism therein (Su LX, et al. 
for publication). Perhaps this new discovery of a noninvasive detection index may have 
potential clinical value for sepsis-related multiple organ dysfunction. 
4. microRNAs  
MicroRNAs (miRNAs) are a type of endogenous non-coding small RNAs that are about 22 
nucleotides in length (Lagos-Quintana et al. 2001) (Ambros 2004). They play important 
biological roles by inhibiting the expressions of messenger RNAs (mRNAs) (Krutzfeldt et al. 
2006). As with mRNAs, some miRNAs are differentially expressed among tissues or 
developmental stages. Unlike some widely expressed miRNAs, these tissue- or 
developmental stage-specific miRNAs likely play key roles in regulating specific processes 
involved in the development or function of individual tissues (Etheridge et al. 2011). The 
liver-specific miR-122 has been applied in lipid and cholesterol metabolism, which are both 
known to be important functions of the liver (Bolmeson et al. 2011; Fernandez-Hernando et 
al. 2011). Because of their unique expression profiles, these miRNAs hold promise as 
diagnostic markers or therapeutic targets for many diseases. For example, miR-122 is 
required in hepatitis C virus (HCV) replication (Cermelli et al. 2011) and reagents that can 
modulate the level of miR-122 have moved into clinical development for HCV treatment 
(Pan et al. 2007; Said 2010; Zhang et al. 2010). miRNAs play an essential role in many 
physical and biological processes; thus, altered miRNA expression levels are associated with 
the occurrence and progression of disease. 
4.1. Circulating miRNAs  
A significant number of miRNAs have been observed outside of cells, within various body 
fluids. These cell-free miRNAs in body fluids are stable under harsh conditions including 
boiling, low or high pH and multiple freeze-thaw cycles (Chen et al. 2008; Mitchell et al. 
2008). At present, there are 2 possible hypotheses for the stability and origin of circulating 
miRNAs. One hypothesis is that passive release occurs during tissue injury. For example, 
miRNA-216a was differentially expressed in the plasma of a pancreatic injury model in rat 
(Kong et al. 2010). miR-122 was also a biomarker for drug-induced liver injury (Wang et al. 
2009). Alternatively, miRNAs are contained in small particles and are, therefore, protected 
against RNase activity. Recently, it has been shown that a transfer of mRNA and miRNA 
between cells can be accomplished through microvesicles (Valadi et al. 2007). These are 
small particles, which are derived from the cell plasma membrane into the extracellular 
space and released into the circulation (Caby et al. 2005; van Niel et al. 2006). Microvesicles 
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are derived from various cell types, e.g. reticulocytes, dendritic cells, B and T cells and mast 
cells (Escola et al. 1998; Valenti et al. 2006; Brase et al. 2010). And in the peripheral blood, 
two-thirds of microvesicles are derived from platelets. Platelet-derived microvesicles play a 
role in angiogenesis and the metastatic spread of cancers (Janowska-Wieczorek et al. 2005). 
Platelet-derived microvesicles induce an immune response upon regulating gene expression 
in hematopoietic, endothelial, and monocytic cells (Setzer et al. 2006; Majka et al. 2007). 
Notably, platelet-derived microvesicle subpopulations are increased in patients with sepsis 
(Janiszewski et al. 2004). However it is currently unknown whether microvesicle content 
changes in these diseases (Hunter et al. 2008). 
4.2. What do we know about the miRNAs as biomarkers for sepsis?  
4.2.1. miRNAs as prognostic biomarkers for sepsis 
Circulating miRNAs have been recently identified as biomarkers for sepsis. miR-150 was 
firstly identified as a prognostic marker for sepsis, and levels of miR-150, as detected by 
microarrays, were significantly different between the leukocytes of healthy controls and 
sepsis patients. In sepsis patients’ plasma, levels of miR-150 were correlated with the level of 
SOFA score, and the plasma level ratio for miR-150/interleukin-18 can be used to evaluate 
sepsis severity (Vasilescu et al. 2009). A recent study demonstrated that miR-
150 differentially controls the development of natural killer (NK) and invariant NKT cell 
(iNKT) lineages by targeting the transcription factor c-Myb (Bezman et al. 2011). Few other 
functional studies about miR-150 in sepsis have been published. However, it has been 
demonstrated that the coding genes of tumor necrosis factor alpha (TNF-a), interleukin-10 
(IL-10), and interleukin-18 (IL-18) have sequence complementarity to miR-150 (Vasilescu, 
Rossi et al. 2009). This finding suggests that miR-150 might be correlated with some of the 
immune system dysfunctions in sepsis patients, and it provides a new potential 
pathogenetic mechanism of sepsis. Hence, additional functional studies of miR-150 are 
required. 
Sepsis is a complex disease that involves various tissues and organs. A simple screen for 
miRNAs differentially expressed in leukocytes may have missed many miRNAs secreted 
by other cell types. Hence, a genome-wide method was used to screen for differentially 
expressed miRNAs between the surviving and non-surviving groups of sepsis patients. 
Then, two novel prognostic biomarkers, miR-297 and miR-574-5p, were identified by 
microarray screening and quantitative real-time reverse transcription polymerase chain 
reaction (qRT-PCR) confirmation (Wang et al. 2012). miR-297 was more closely correlated 
with survival from sepsis, whereas miR-574-5p was correlated with death from sepsis. 
After analysis in a multivariable logistic regression model, results showed that a 
combination of sepsis stage, SOFA scores, and miR-574-5p were correlated with the death 
of sepsis patients. The predictive capability of these 3 combined variables was analyzed 
by a ROC curve; the area under the curve was 0.932 (95% CI, 0.887-0.977). When the cutoff 
point was set at 0.288, these 3 combined variables provided 78.13% sensitivity and 91.84% 
specificity.  
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In summary, a genome-wide scan of sepsis patients’ sera demonstrated that 2 miRNAs, 
miR-297 and miR-574-5p, might be related to the prognosis of sepsis in a genetic way. 
Identification of these miRNAs could provide more therapeutic targets for sepsis. 
4.2.2. miRNAs as diagnostic biomarkers for sepsis 
As diagnostic biomarkers for sepsis, levels of these markers should be not only differentially 
expressed between sepsis patients and healthy controls, but also between sepsis patients 
and SIRS patients. Levels of miR-146a and miR-223 in sepsis patients’ sera were significantly 
decreased compared to SIRS patients and healthy controls. These levels were evaluated by 
qRT-PCR in 50 sepsis patients and 30 SIRS patients. The areas under the ROC curve for miR-
146a and miR-223 were 0.858 and 0.804, respectively, which were both higher than IL-6 with 
an AUC of 0.785 (Wang et al. 2010). miR-146a regulates a pathway that promotes the 
binding of transcription repressor RelB to the TNF-α promoter, which generates facultative 
heterochromatin to silence acute proinflammatory genes (El Gazzar et al. 2011). This 
mechanism was proved in the THP-1 sepsis cell model of bacterial LPS/endotoxin tolerance. 
During LPS tolerance, transcriptional- and translation-repressive events combine to tightly 
regulate proinflammatory genes, which was a common feature of severe systemic 
inflammation (El Gazzar and McCall 2010). Hence, miR-146a was an important regulator 
during sepsis. Although the source and the release mechanism of miR-146a remain 
unknown, its clinical value is undeniable. 
miR-15a and miR-16 are also newly identified diagnostic markers for sepsis. Levels of these 
2 miRNAs in sepsis and SIRS patients were both significantly higher than in normal 
controls. And miR-15a can be used to distinguish sepsis patients from SIRS patients. The 
area under the ROC curve for miR-15a was 0.858, which was much higher than the curves 
for CRP and PCT. These results were obtained from 166 sepsis patients and 32 SIRS patients 
(Wang et al, 2012). miR-15a and miR-16 were initially identified as tumor suppressors, and 
the dysregulation of these two miRNAs has been found to occur in many types of cancer 
(Calin et al. 2002; Bottoni et al. 2005; Bhattacharya et al. 2009; Yang et al. 2010; Bandi and 
Vassella 2011). Recently, decreases in miR-15a, miR-16 and miR-223 were found to be 
associated with the innate immune system by targeting IκB kinase alpha (IKKα) mRNA, 
which is involved in the non-canonical NF-κB signaling pathway (Li et al. 2010). IκB kinase 
(IKK) is an enzyme complex that is part of the upstream NF-κB pathway. IκBα (inhibitor of 
kappa B) protein can inactivate NF-κB, and IKK can phosphorylate the inhibitory IκBα 
protein. Besides that, there is still no direct evidence for the correlations between miR-15a 
and miR-16 and sepsis. Hence, more functional studies of miR-15a and miR-16 need to be 
done.  
For sepsis patients, timely diagnosis and early treatment are very important factors to 
improve their prognosis. miRNAs are newly identified as the main regulators of the 
immune system, and altered expression profiles in circulation can be used as diagnostic and 
prognostic biomarkers for sepsis. Although the functions of these miRNAs are not 
completely understood, their clinical value has been confirmed. New biomarkers also mean 
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novel treatment targets. Hence, target genes of these miRNAs may emerge as potential 
treatment targets for sepsis patients. 
5. SNPs 
A single nucleotide polymorphism (SNP) is the most common type of stable genetic 
variation in the population. Thus, SNPs explain different sequence alternatives (alleles) 
existing at single base pair positions in genomic DNA in normal individuals in some 
populations. They are distinguished from rare variations by a requirement for the least 
abundant allele to have a frequency of 1% or more.(Brookes 1999)  
A SNP occurs in approximately 1 of 1000 base pairs, with the most frequent being a C to T 
substitution. Polymorphisms, which occur both in the coding and non-coding genome 
regions, involve replacement of a nucleotide with another one, or insertion or deletion of 1 
or more nucleotides. Because of a higher degree of preservation of exons to assure the 
functionality of genes, the frequency of polymorphisms in the non-coding regions is much 
higher compared with the coding ones. But changes in non-coding regions interfere with the 
structure and process of transcription and gene expression; thus, polymorphisms and 
mutations in non-coding regions may also produce a marked effect on phenotype 
presentations.(Prucha et al. 2008)  
5.1. Categories of SNPs 
SNPs are divided into two main categories, linked SNPs and causative SNPs. Linked SNPs 
(also called indicative SNPs) are located outside genes and do not affect protein function. 
Nevertheless, they are associated with a particular drug response or with the risk for getting 
a certain disease. 
Causative SNPs affect the function of protein, correlating with a disease or influencing a 
person's response to medication. There are 2 forms of causative SNPs, coding SNPs (cSNPs) 
and non-coding SNPs. Coding SNPs, located in the coding region of a gene, can change the 
amino acid sequence of a gene's protein product;  this type of SNP attracts more research 
than non-coding SNPs. Non-synonymous cSNPs (nsSNPs), which change the amino acid 
sequence of proteins and are likely to affect the structure and function of the proteins, are 
good candidates for disease-modifying alleles.(Jegga et al. 2007) And non-coding SNPs, 
located in the gene's regulatory sequences, also can change the level of gene expression. 
Because only about 3% to 5% of a person's DNA sequence codes for the production of 
proteins, most SNPs are found outside of coding sequences. 
5.2. Influence of SNPs 
Single nucleotide substitutions may influence complex diseases by a variety of mechanisms. 
First, the amino acid sequence of some proteins whose functions include DNA binding, 
catalytic activity and receptor–ligand contact may be reduced or abolished by SNPs. Second, 
SNPs can interfere with the initiation or the termination codon or introduce errors in the 
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reading frameshift. Third, mutations in known promoter motifs that alter DNA binding of 
transcription factors have the potential for decreasing or increasing gene expression. Finally, 
RNA cleavage-polyadenylation mutants in the untranslated region of the 5' UTR are 
thought to play a role in controlling mRNA translation while sequence variants in the 3' 
UTR control RNA cleavage, stability, export and intracellular localization.(Wjst 2004) It is 
reported that only 10% of all gene-based SNPs have sequence-predicted functional relevance 
making them a primary target for genotyping in association studies. (Wjst 2004) There has 
been an effort to explain the potential causal relationship between the genetic changes and 
the development and course of diseases in order to modulate a patient’s response to 
administration of drugs.(Sachidanandam et al. 2001)  
5.3. Researches in SNPs 
Genome-wide association (GWA) studies have been used to compare patient populations. 
The International HapMap Project and the arrival of technologies that type more than 
100,000 SNPs in a single experiment have made genome-wide single nucleotide 
polymorphism (GW-SNP) assay a realistic endeavor. (Gibbs and Singleton 2006) 
5.4. SNPs as biomarkers for sepsis  
More than 20 years ago, Sorensen and colleagues reported that if one of an adult adoptee’s 
biologic parents died of infection before the age of 50, the adoptee had a 5.81-fold increased 
risk of dying from infection.(Sorensen et al. 1988) Current sepsis-related polymorphism 
studies have most commonly focused on one or more polymorphisms for specific genes 
whose protein products are elements of biologic pathways implicated in sepsis. Many of 
these studies are association studies where various proinflammatory cytokines and their 
receptors, novel biomarkers, enzymes and mediators were compared with the development 
and clinical outcomes of sepsis, severe sepsis and organ dysfunction. In particular, 
identification of genetic variation in the Toll-like receptors (TLRs) and proinflammatory 
cytokines has provided valuable insights into the influence of genetic heterogeneity on the 
response to bacterial infection. And sometimes, different conclusions were given in 
researching the same SNP. Analyzing the variation in genes and associated differences in 
response to infection may contribute to the development of new gene diagnosis and 
therapeutic interventions that will improve outcome in this patient population. 
5.4.1. TLRs  
Expressed by macrophages, dendritic cells, neutrophils, and other cell populations, TLRs 
play a central role in the innate immune response to infection through the recognition of 
distinct bacterial antigens. (Leulier and Lemaitre 2008) TLR4 is crucial for the recognition of 
lipopolysaccharide (LPS), while TLR2 is essential in the recognition of Gram-positive 
bacterial components.(Martin 2000; Opal and Huber 2002) In an American research study, 
human subjects with 2 TLR mutations (299 Asp→Gly and 399 Thr→Ile) were compared to 
subjects with TLR4 wild type for response to inhaled toxins. The changes in 299 Asp→Gly, 
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but not 399 Thr→Ile, significantly reduced nuclear levels of NF-kB in LPS-stimulated THP-1 
cells. The 299/399 polymorphisms had reduced levels of IL-1a associated with 
hyporesponsiveness to inhaled endotoxin in humans. (Arbour et al. 2000) Patients with 
septic shock with the TLR4 Asp299Gly/Thr399Ile alleles had a higher prevalence of gram-
negative infections.(Lorenz et al. 2002) Furthermore, the TLR4 299 polymorphism has been 
reported to be associated with severe sepsis, septic shock and a higher mortality in septic 
patients with SIRS. (Lorenz, Mira et al. 2002; Child et al. 2003; Barber et al. 2004) Some 
studies illustrate that TLR2 753 Arg→Gln and 677 Arg→Trp may predispose individuals to 
certain gram-positive infections such as tuberculosis or leprosy.(Ben-Ali et al. 2004; Ogus et 
al. 2004) 
5.4.2. Cytokines 
A key role in the pathogenesis of sepsis is the balance or imbalance of pro- and anti-
inflammatory cytokines. Disorders of coagulation are common in sepsis, and 30% to 50% of 
patients have the more severe clinical form, disseminated intravascular coagulation.(Levi et 
al. 2000) 
TNF-α 
TNF-α, a pleiotropic cytokine mainly produced by activated monocytes and macrophages, 
plays a key role in the inflammatory response, and its overexpression  can lead to the 
progression of inflammatory and autoimmune diseases.(Locksley et al. 2001; O'Shea et al. 
2002) But the association between TNF gene polymorphisms and morbidity or clinical 
outcome of sepsis was not so clearly defined. An association between development of 
sepsis, but not mortality from sepsis, and the TNF2 genotype in the overall population was 
found.(Teuffel et al. 2010) An Austrian study discovered that peak values of inflammatory 
and coagulation markers were not different between wild-type TNF- -308 individuals (GG) 
and carriers of the TNF- -308 mutant allele (GA and AA).(Kovar et al. 2007)  
IL-1 and receptor 
The interleukin-1 (IL-1) receptor-associated kinase 1 (IRAK1) is believed to play an 
important role in TLR2- and TLR4-induced activation of NF-ĸB, a critical event in the 
transcriptional regulation of many sepsis-associated proinflammatory mediators.(Arcaroli et 
al. 2006) Alleles A2, B2 and RN2 in the IL-1 gene might be important high-risk genetic 
markers for sepsis.(Ma et al. 2002) IRAK1 might be a genetic risk factor for the occurrence 
and development of sepsis in the Chinese population. (Arcaroli, Silva et al. 2006) 
IL-10 
Interleukin-10 (IL-10) is an anti-inflammatory cytokine produced by macrophages and T-
helper-type II (TH2) lymphocytes that can downregulate inflammatory production, which 
plays a very important role in the process of induction of immunoparalysis. (Nicod et al. 
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1995; Thomassen et al. 1996) Three SNPs (–1082, –819, and –592) were found in the 
regulatory region of the IL-10 gene. The A allele of the -1082 polymorphism in the IL-10 
gene promoter is associated with late blood stream infections in ventilated, very low-birth-
weight infants and with sepsis susceptibility, whereas the G allele is associated with higher 
stimulated IL-10 production and increased mortality in severe sepsis.(Shu et al. 2003; 
Stanilova et al. 2006) Otherwise, the -1082G/G genotype has been associated with lower 
mortality and organ failure among the subjects with acute respiratory distress 
syndrome.(Gong et al. 2006) The A allele of the single nucleotide polymorphism at -592 base 
pairs was associated with higher mortality in sepsis.(Lowe et al. 2003) 
Sepsis, an increasing cause of mortality in patients with infectious diseases, especially in 
seriously ill patients in the ICU, requires rapid diagnosis and treatment. Because SNPs occur 
frequently throughout the genome and tend to be relatively stable genetically, they can be 
used as excellent biological markers in sepsis. Depending on rapid advances in technology 
and informatics, the primary goal in the management of sepsis may change from rapid 
treatment to prevention for those most at risk. The health care cost savings from such 
changes could be substantial. 
6. Conclusion 
In conclusion, the search for new biomarkers for assessing the severity of sepsis patients and 
predicting prognosis is very important, interesting, and challenging work, providing new 
insights to confront sepsis. 
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